Zoom Logo

MFBM CT-3 - Shared screen with speaker view
Laura Strube (she/her)
27:56
I'm interested in how this might be applied to experiment design?
Laura Strube (she/her)
28:03
Any insights?
Dimitris Patsatzis
29:31
How computationally efficient is this approach, in comparison say with pseudo-arc length?
Gregg Szep
42:53
how many models share the same asymptotic behaviour?
Gregg Szep
44:34
thank you :)
Lea Sta
45:01
ok I answered to your question?
Gregg Szep
45:01
what computational tools did you use to fit parameters?
Lea Sta
46:23
we fitted the parameter with least square regression ( to be confirmed, Guillaume did it) , I confirmed it by doing Approximate bayesian computation
Laura Strube (she/her)
46:37
Lea - I really enjoyed your talk. Could you restate the biological differences between your simple and more complex models? Did the simple include only one gamma chain per complex, and the second include two gamma chains per complex? I missed that detail.
Gregg Szep
46:43
I think so! I was just wondering how generic this limit is that you showed.. and I think the answer was "not generic, specific to the model you outlined"
Lea Sta
49:07
No, the first model is composed of gamma alpha, jak and the ligand IL-7. they bind in a certain order and we allow signaling and dummy receptors to be formed. The new model is the same but we also allow an additional component R (which could account for IL-2Rbeta or IL-'Ralpha or whatever can bind to the gamma and is in a sort of competition with the IL-7Ralpha). This additional R binds to gamma or gamma:JAK only.
Lea Sta
50:34
If it is not clear, I am happy to discuss after the talks. you can send me emails at mmls@leeds.ac.uk.
Laura Strube (she/her)
50:45
Thanks!